Report cover image

Hypertriglyceridemia Therapeutics Market

Publisher Coherent Market Insights
Published Jul 19, 2023
Length 230 Pages
SKU # CMI18107933

Description

Hypertriglyceridemia Therapeutics Market, By Type (Primary and Secondary), By Drug Class (Statins, Fibrates, Omega-3 Fatty Acids, HMG-CoA Reductase inhibitors, and Niacin), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030


Hypertriglyceridemia is a common disorder in which the triglyceride levels in the body increase. It is often caused or exacerbated by uncontrolled diabetes mellitus, obesity, and sedentary habits, all of which are more prevalent in industrialized societies than in developing nations. This rising levels of triglyceride are majorly associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. Hypertriglyceridemia also causes pancreatitis, atherosclerosis, and other cardiovascular diseases. Currently, the advancements in treatment of hypertriglyceridemia are helping in recovering the triglyceride levels in the human body. Severe hypertriglyceridemia means your triglycerides are 500 mg/dL or higher. People with severe hypertriglyceridemia face an increased risk of acute pancreatitis. This is a pancreatic inflammation that needs medical attention. Most people with hypertriglyceridemia have no symptoms. People with severe hyperglyceridemia may develop xanthomas. These are skin bumps that form when lipids build up under your skin. The xanthomas usually appear around your eyelids. But they may also appear on your knees, elbows or palms of your hands. Genetics- increased triglyceride levels in the blood may be associated with certain genetic diseases or disorders, such as familial combined hyperlipidemia.

Market Dynamics

The ongoing research & development of developing novel drugs is expected to propel the global hypertriglyceridemia market growth during the forecast period. Further, growing prevalence of cardiovascular diseases such as atherosclerosis, hypertension, and coronary heart disease and sedentary lifestyle is also expected to boost the global hypertriglyceridemia therapeutics market over the forecast period. For instance, in February 2020, Esperion Therapeutics, Inc., a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies, announced that the U.S. Food and Drug Administration (FDA) approved NEXLETOL (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.

Key features of the study:
  • This report provides in-depth analysis of the global hypertriglyceridemia therapeutics market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hypertriglyceridemia therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Sanofi, GSK, plc., Biocon, Novo Nordisk A/S, Tonghua Dongbao Pharmaceutical Co., Ltd., Oramed, AbbVie Inc., Merck & Co., Inc. WOCKHARDT, Pfizer Inc., Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company, ADOCIA, Hikma Pharmaceuticals PLC, Lupin, Zydus Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC., Aurobindo Pharma, and Accord Healthcare.
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global hypertriglyceridemia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypertriglyceridemia therapeutics market
Detailed Segmentation:
  • Global Hypertriglyceridemia Therapeutics Market, By Type:
  • Primary
  • Secondary
  • Global Hypertriglyceridemia Therapeutics Market By Drug Class:
  • Statins
  • Fibrates
  • Omega-3 Fatty Acids
  • HMG-CoA Reductase inhibitors
  • Niacin
  • Global Hypertriglyceridemia Therapeutics Market By Distribution Channel:
  • Retail Pharmacy
  • Hospitals Pharmacy
  • Online Pharmacy
  • Others
  • Global Hypertriglyceridemia Therapeutics Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Sanofi
  • GSK, plc.
  • Biocon
  • Novo Nordisk A/S
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Oramed
  • AbbVie Inc.
  • Merck & Co., Inc.
  • WOCKHARDT
  • Pfizer Inc.
  • Julphar
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • ADOCIA
  • Hikma Pharmaceuticals PLC
  • Lupin
  • Zydus Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals LLC.
  • Aurobindo Pharma
  • Accord Healthcare

Table of Contents

230 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Type
Market Snapshot, By Drug Class
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Market Attractiveness Analysis
Merger, Acquisition, Collaborations
Funding and Investment
Regulatory Guidelines and Compliances
Key Developments
Pipeline Analysis
PEST Analysis
PORTER’s Analysis
4. Global Hypertriglyceridemia Therapeutics Market– COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Global Hypertriglyceridemia Therapeutics Market, By Type, 2018-2030, (US$ Billion)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018-2030
Segment Trends
Primary
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Secondary
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
6. Global Hypertriglyceridemia Therapeutics Market, By Drug Class, 2018-2030, (US$ Billion)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018-2030
Segments Trends
Statins
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Fibrates
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Omega-3 Fatty Acids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
HMG-CoA Reductase inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Niacin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
7. Global Hypertriglyceridemia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Billion)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018-2030
Segments Trends
Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Hospitals Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
8. Global Hypertriglyceridemia Therapeutics Market, By Region, 2018-2030, (US$ Billion)
Introduction
Market Share Analysis, By Region, 2023 and 2030 (%)
Y-o-Y Growth Analysis, For Region, 2018–2030
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Billion)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Sanofi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
GSK, plc.
Biocon
Novo Nordisk A/S
Tonghua Dongbao Pharmaceutical Co., Ltd.
Oramed
AbbVie Inc.
Merck & Co., Inc.
WOCKHARDT
Pfizer Inc.
Julphar
Eli Lilly and Company
Bristol-Myers Squibb Company
ADOCIA
Hikma Pharmaceuticals PLC
Lupin
Zydus Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Ltd.
Amneal Pharmaceuticals LLC.
Aurobindo Pharma
Accord Healthcare
10. Section
Research Methodology
About Us
*Browse 32 market data tables and 26 figures on “Global Hypertriglyceridemia Therapeutics Market”- Global forecast to 2030

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us